Caribou Biosciences Inc Quick Ratio (CRBU) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Caribou Biosciences Inc   (NASDAQ: CRBU)

Caribou Biosciences Inc 's Quick Ratio

CRBU's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Caribou Biosciences Inc 's Cash & cash equivalent, this led to improvement in Caribou Biosciences Inc 's Quick Ratio to 6.33, Quick Ratio remained below Caribou Biosciences Inc average.

Within Biotechnology & Pharmaceuticals industry 55 other companies have achieved higher Quick Ratio than Caribou Biosciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 573 to 602.

Explain Quick Ratio?
How much Cash & cash equivalents CRBU´s has?
What are CRBU´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CRBU Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -37.78 % -30.95 % -17.09 % -12.75 % -6.65 %
Y / Y Cash & cash equivalent Change -38.13 % -43.58 % -33.5 % -35.46 % -29.7 %
Quick Ratio MRQ 6.33 5.98 5.48 5.25 6.37
CRBU's Total Ranking # 602 # 573 # 561 # 535 # 413
Seq. Current Liabilities Change -8.64 % -22.59 % -9.42 % -2.87 % 1.39 %
Seq. Cash & cash equivalent Change -3.25 % -15.58 % -5.38 % -19.95 % -11.76 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 56
Healthcare Sector # 258
Overall Market # 602


Quick Ratio Statistics
High Average Low
16.64 8.76 1.2
(Sep 30 2021)   (Dec 31 2020)




Financial Statements
Caribou Biosciences Inc 's Current Liabilities $ 18 Millions Visit CRBU's Balance sheet
Caribou Biosciences Inc 's Cash & cash equivalent $ 114 Millions Visit CRBU's Balance sheet
Source of CRBU's Sales Visit CRBU's Sales by Geography


Cumulative Caribou Biosciences Inc 's Quick Ratio

CRBU's Quick Ratio for the trailling 12 Months

CRBU Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -24.19 % -16.53 % -9.71 % -6.77 % 2.78 %
Y / Y Cash & cash equivalent TTM Growth -37.6 % -35.21 % -31.64 % -32.66 % -32.12 %
Quick Ratio TTM 5.69 5.76 6.13 6.45 6.91
Total Ranking TTM # 3613 # 3586 # 2760 # 2896 # 2780
Seq. Current Liabilities TTM Growth -10.7 % -7.95 % -4.51 % -3.41 % -1.68 %
Seq. Cash & cash equivalent TTM Growth -11.93 % -13.38 % -9.37 % -9.75 % -8.56 %

Quick ratio ranking by company, industry and sector >> Back to CRBU Financial Strength Comparisons >> Go to Compare CRBU Quick Ratio to its Competitors

  News about Caribou Biosciences Inc Quick Ratio

Evaluating Caribou Biosciences Insights From Financial Analysts

Caribou Biosciences Inc., a biopharmaceutical company focused on CRISPR genome-editing technology, has recently garnered attention from financial analysts. This article aims to provide a comprehensive analysis of Caribou Biosciences based on insights from notable financial analysts and recent developments.Financial Analysts 12-Month Price Targets:According to a report published on July 17, 2024, financial analysts have revealed their 12-month price targets for Caribou Biosciences. The average target stands at $15.25, with a high estimate of $24.00 and a low estimate of $9.00. This current average suggests a potential increase of 19.74%. These price targets indicate a positive sentiment among analysts regarding the future prospects of Caribou Biosciences.

On the trailing twelve months basis In spite of the year on year decrease in CRBU's Current Liabilities to $17.97 millions, cumulative Quick Ratio to 5.69 below the CRBU average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Caribou Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3586 to 3613.

Explain Quick Ratio?
How much Cash & cash equivalents CRBU´s has?
What are CRBU´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 140
Healthcare Sector # 861
Within the Market # 3613


trailing twelve months Quick Ratio Statistics
High Average Low
14 9.03 5.32
(Jun 30 2022)   (Sep 30 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Aura Biosciences Inc   16.56 $ 323.840  Millions$ 19.560  Millions
Kalaris Therapeutics Inc   16.46 $ 143.865  Millions$ 8.738  Millions
Kyverna Therapeutics Inc   16.10 $ 367.021  Millions$ 22.802  Millions
Tectonic Therapeutic Inc   15.96 $ 227.068  Millions$ 14.224  Millions
Candel Therapeutics Inc   15.89 $ 201.565  Millions$ 12.685  Millions
Inhibikase Therapeutics Inc   15.50 $ 159.019  Millions$ 10.260  Millions
Voyager Therapeutics Inc   13.75 $ 229.369  Millions$ 16.685  Millions
Leonabio Inc   13.07 $ 102.167  Millions$ 7.817  Millions
Lenz Therapeutics Inc   12.82 $ 220.651  Millions$ 17.212  Millions
X4 Pharmaceuticals Inc  11.41 $ 220.874  Millions$ 19.366  Millions
Quince Therapeutics Inc   11.30 $ 116.000  Millions$ 10.262  Millions
Compass Therapeutics Inc   11.15 $ 179.879  Millions$ 16.128  Millions
Odyssey Therapeutics, Inc.  10.98 $ 310.575  Millions$ 28.295  Millions
Protara Therapeutics Inc  10.70 $ 142.494  Millions$ 13.319  Millions
Engene Therapeutics Inc   9.79 $ 266.320  Millions$ 27.209  Millions
Eikon Therapeutics Inc   9.61 $ 531.178  Millions$ 55.296  Millions
Zura Bio Limited  9.46 $ 205.134  Millions$ 21.690  Millions
4d Molecular Therapeutics Inc   9.16 $ 436.624  Millions$ 47.673  Millions
Fate Therapeutics Inc   8.44 $ 275.141  Millions$ 32.592  Millions
Monte Rosa Therapeutics Inc   8.32 $ 1,152.100  Millions$ 138.548  Millions
Cullinan Therapeutics Inc   8.23 $ 334.500  Millions$ 40.628  Millions
Prokidney Corp   7.99 $ 181.564  Millions$ 22.710  Millions
In8bio Inc   7.97 $ 17.956  Millions$ 2.254  Millions
Denali Therapeutics Inc   7.89 $ 710.471  Millions$ 90.083  Millions
Redwoods Acquisition Corp  7.69 $ 9.300  Millions$ 1.210  Millions
Cardiff Oncology Inc   7.04 $ 76.005  Millions$ 10.797  Millions
Black Diamond Therapeutics Inc   6.98 $ 110.506  Millions$ 15.843  Millions
Immunovant Inc   6.81 $ 797.798  Millions$ 117.102  Millions
Scholar Rock Holding Corp  6.81 $ 492.088  Millions$ 72.242  Millions
Fennec Pharmaceuticals Inc   6.66 $ 82.498  Millions$ 12.394  Millions

Date modified: 2026-09-02T20:50:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.